What is Oncology Research?

Oncology Research (oncologyresearch.us) is a free web platform that provides healthcare professionals, researchers, and students with real-time access to peer-reviewed cancer research articles from PubMed, enhanced with AI-powered summarization, clinical trial cross-referencing from ClinicalTrials.gov, and personal research management tools.

What cancer types does Oncology Research cover?

The platform provides focused filtering for breast cancer, lung cancer, brain cancer (glioblastoma, CNS tumors), leukemia (ALL, AML, CLL, CML), lymphoma (Hodgkin and Non-Hodgkin), prostate cancer, and colorectal cancer, while also supporting searches across all cancer types indexed in PubMed.

Where does Oncology Research get its article data?

All article data is sourced in real-time from PubMed's E-utilities API operated by the U.S. National Library of Medicine at the National Institutes of Health. Clinical trial data comes from the ClinicalTrials.gov API. The platform does not publish original research.

What AI features does Oncology Research offer?

Oncology Research uses Google Gemini 2.5 Flash to generate plain-language summaries of complex research abstracts with one click. The platform also provides oncology-specific search autocomplete suggestions, smart keyword-based related article discovery, and automated clinical trial matching from ClinicalTrials.gov.

How do I cite articles found on Oncology Research?

Each article page provides one-click citation export in BibTeX, RIS, APA, and MLA formats. You can also bulk export your entire bookmark library in CSV, BibTeX, or RIS format. When citing specific research findings, cite the original article using its PMID or DOI.

Trastuzumab Botidotin vs T-DM1: Longer PFS, HER2+ Breast

Trastuzumab Botidotin Extends PFS Versus T-DM1 (HR 0.39) in Previously Treated HER2-Positive Advanced Breast Cancer, With Immature Overall Survival Data

How this article was produced

This article was written about a single named primary publication, with AI assistance for literature discovery, drafting and editing. AI tools are not the author and are not responsible for the conclusions.

How the draft was prepared

Discovery: PubMed is searched for oncology publications from the previous 14 days in a fixed list of major journals — JAMA Oncology, The Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, Nature Reviews Clinical Oncology, New England Journal of Medicine, Nature Medicine, Cancer Discovery and Clinical Cancer Research — falling back to a named set of open-access journals only if that list yields nothing. Candidates are ranked by how completely they report quantitative results, and studies already covered are excluded.
Source: the article is drafted from the open full text in PubMed Central where one exists. Where only the abstract is available, it is supplemented with cited external sources — the trial registry record, conference abstracts, sponsor releases — and facts drawn from those sources are labelled as such.
Numbers are reported exactly as the source gives them, with confidence intervals and p-values, and are not rounded. Data the source does not report is stated as not specified rather than estimated.
Subgroup statistics are reported only where the source states them explicitly, and quotations are reproduced verbatim.
Benchmarks from other studies are labelled as cross-study comparisons and never presented as results of the trial itself.
Validation: every factual claim in the draft is checked against the source, and key claims are spot-checked against independent sources such as the trial registry. Fixable discrepancies are corrected before the draft is handed on for publication.

These steps are instructions followed by an AI system, not checks enforced by software. The validation step is itself performed by AI rather than a person, and its verdict does not by itself stop an article from being published. This describes the current workflow; some earlier articles predate parts of it.

Checks completed before publication

The primary publication is recorded in structured form — journal, publication date, DOI, PubMed ID and PMC ID where they exist — rather than only as prose in a reference list.
Every cited DOI is confirmed to resolve.
Every cited PubMed ID is confirmed to exist in PubMed.
The cited DOI is cross-checked against the DOI that PubMed records for that PubMed ID, so a citation cannot point at a different paper from the one the article describes.
Trial registry identifiers are format-checked and linked to their ClinicalTrials.gov record.
Every reference must carry a resolvable identifier or link, unless it is explicitly labelled as a funding note, press release or background statistic.
The article must contain a limitations discussion specific to the study — what it could not establish — not a generic disclaimer.
Absolutist claims such as “proves”, “guarantees”, “will cure” or “completely effective” are rejected.
HTML markup and entities that would render as literal text — such as an unsupported tag or " " — are rejected outside the reference list.
Structural checks confirm the article has a unique URL and complete metadata.

These run automatically on every article. If any of them fails, the build fails and the article is held rather than published.

What these checks do not cover

These checks confirm that the sources are real and correctly cited. They do not confirm that the analysis drawn from them is sound. This article has not been read against its primary source by a human editor, and should be read as a signpost to the primary publication rather than a substitute for it.

Evidence note

This article summarizes research findings and does not provide medical advice or treatment recommendations. Investigational findings, preliminary results, and preclinical evidence should not be interpreted as established clinical care. Always consult the cited primary source, and a qualified clinician, before acting on anything described here.

Corrections

Report a factual error or a sourcing concern through our corrections policy. Substantive corrections are dated and described on the article page. Our editorial policy explains how these articles are sourced, verified, and corrected.

Article Summary

In a phase III, open-label, randomized trial at 57 centers in China, 365 patients with HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab and a taxane were randomized 1:1 to trastuzumab botidotin (n = 182) or trastuzumab emtansine (n = 183). Median PFS by blinded independent central review was 11.1 vs 4.4 months (HR 0.39; 95% CI, 0.30 to 0.51; nominal P < .0001), and objective response rate was 76.9% vs 53.0%.
Overall survival data were immature (HR 0.62; 95% CI, 0.38 to 1.03; medians not reached). Grade ≥3 treatment-emergent adverse events occurred in 69.8% vs 63.7%, and ocular treatment-related events had a high incidence with trastuzumab botidotin. The trial was open-label with a median follow-up of 14.9 months, and this article is based on the published abstract plus labeled external sources.

Why This Study Matters

Trastuzumab emtansine (T-DM1) served as the active comparator in this trial, which enrolled patients with HER2-positive unresectable or metastatic breast cancer who had already received trastuzumab and a taxane. The investigators set out to evaluate the safety and efficacy of trastuzumab botidotin, a novel HER2-directed antibody-drug conjugate, in that previously treated setting. The sponsor is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (external source: ClinicalTrials.gov record).

A prespecified interim analysis of PFS per blinded independent central review had already met its superiority boundary (P < .0001). The publication reports the prespecified final PFS analysis.

Median PFS by blinded independent central review: 11.1 vs 4.4 months (HR 0.39; 95% CI, 0.30 to 0.51; nominal P < .0001).

Objective response rate: 76.9% (95% CI, 70.1 to 82.8) vs 53.0% (95% CI, 45.5 to 60.4).

Overall survival data were immature: HR 0.62 (95% CI, 0.38 to 1.03); medians not reached in either group.

Grade ≥3 treatment-emergent adverse events: 127 (69.8%) vs 116 (63.7%); ocular treatment-related events had a high incidence with trastuzumab botidotin.

Study Design

Element	Detail	Source
Phase / design	Phase III, open-label, multicenter, randomized controlled trial	Published abstract
Sites	57 centers in China	Published abstract
Randomization	1:1 to trastuzumab botidotin or trastuzumab emtansine	Published abstract
Primary endpoint	Progression-free survival (PFS) by blinded independent central review (BICR), intention-to-treat	Published abstract
Enrollment window	July 18, 2023 to April 26, 2024	Published abstract
Dosing	Trastuzumab botidotin 4.8 mg/kg every 3 weeks vs T-DM1 3.6 mg/kg every 3 weeks	External reporting (ASCO Post)
Stratification factors	Not specified in source	Published abstract

Patient Population

Adults with HER2-positive unresectable or metastatic breast cancer who had received prior trastuzumab and a taxane. A total of 365 patients were randomly assigned: 182 to trastuzumab botidotin and 183 to trastuzumab emtansine. Eligible age range was 18 to 75 years (external source: ASCO Post). Baseline characteristic tables (e.g., lines of prior therapy, visceral disease prevalence) are not specified in the available sources.

Study at a glance

365 patients randomized (182 vs 183); 57 centers in China; 1:1 randomization, open-label; median follow-up 14.9 months.

Primary Endpoint Results

At data cutoff (median follow-up, 14.9 months), trastuzumab botidotin produced longer PFS than trastuzumab emtansine: median 11.1 vs 4.4 months (hazard ratio, 0.39 [95% CI, 0.30 to 0.51]; nominal P < .0001).

Outcome	Trastuzumab botidotin (n = 182)	T-DM1 (n = 183)	Source
Median PFS (BICR)	11.1 months	4.4 months	Published abstract
PFS hazard ratio	0.39 (95% CI, 0.30 to 0.51); nominal P < .0001	Reference	Published abstract
Objective response rate	76.9% (95% CI, 70.1 to 82.8)	53.0% (95% CI, 45.5 to 60.4)	Published abstract
Estimated 6-month PFS	69.7%	39.7%	External reporting (ASCO Post)
Median duration of response	12.2 months	5.7 months	External reporting (ASCO Post)
Overall survival	HR 0.62 (95% CI, 0.38 to 1.03); medians not reached; data immature	Reference	Published abstract

Subgroup Analyses

The abstract states that benefit was consistent across subgroups, including those defined by prior lines of anti-HER2 therapy, prior pertuzumab or anti-HER2 tyrosine kinase inhibitors, and visceral metastases. Subgroup-level hazard ratios and confidence intervals are not reported in the abstract or the external sources reviewed.

Subgroup	Reported result
Prior lines of anti-HER2 therapy	Consistent benefit (qualitative); numeric HR: Not specified in source
Prior pertuzumab or anti-HER2 TKIs	Consistent benefit (qualitative); numeric HR: Not specified in source
Visceral metastases	Consistent benefit (qualitative); numeric HR: Not specified in source

Safety Profile

Grade ≥3 treatment-emergent adverse events occurred in 127 (69.8%) patients receiving trastuzumab botidotin and 116 (63.7%) receiving trastuzumab emtansine. Ocular treatment-related adverse events had a high incidence with trastuzumab botidotin; with a protocol-defined management algorithm, most events generally recovered or resolved. Trastuzumab botidotin had low incidences of pulmonary, hematologic, hepatic, and GI toxicities.

Adverse event measure	Trastuzumab botidotin	T-DM1	Source
Grade ≥3 TEAEs	127 (69.8%)	116 (63.7%)	Published abstract
Corneal disorders	92.9%	Not specified in source	External reporting (ASCO Post)
Dry eye	61.5%	Not specified in source	External reporting (ASCO Post)
Corneal disorder, grade ≥3	37.9%	Not specified in source	External reporting (CancerNetwork)
Dry eye, grade ≥3	30.2%	Not specified in source	External reporting (CancerNetwork)
Treatment-related AEs leading to discontinuation	1.1%	3.8%	External reporting (CancerNetwork)

Per the ASCO Post and CancerNetwork summaries, none of the most common ocular events led to treatment discontinuation (external source: ASCO Post; CancerNetwork). Cross-study caution: these percentages come from news summaries of the publication, not from the abstract.

Interpretation and Broader Context

Among patients with HER2-positive advanced BC previously treated with trastuzumab and a taxane, trastuzumab botidotin resulted in significantly longer PFS than trastuzumab emtansine, with a distinct safety profile.
— Conclusion of the published abstract (Zhang et al., J Clin Oncol 2026)

The PFS result was substantial and accompanied by a higher objective response rate. Regulatory status of trastuzumab botidotin: Not specified in source. Future directions: Not specified in source beyond maturation of overall survival data.

Limitations

The trial was open-label, conducted at 57 centers in China, and median follow-up was 14.9 months. Overall survival data were immature, and the OS hazard ratio confidence interval (0.38 to 1.03) crosses 1. The ocular toxicity burden with trastuzumab botidotin was substantial and required a protocol-defined management algorithm. Whether these results generalize to populations outside China is not addressed in the available sources. Subgroup hazard ratios were not reported, and this article draws on the published abstract only because full text was not openly available.

Trial registration

NCT06968585

References

Zhang J, Ouyang Q, Zhang Q, et al. Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial. J Clin Oncol. 2026. doi: 10.1200/JCO-26-00602. PubMed 42727044. ClinicalTrials.gov NCT06968585.
External source: The ASCO Post, September 2026.
External source: CancerNetwork, September 2026.